TY - JOUR
T1 - Institutional Profile
T2 - The International Society for Cellular Therapy: Evolving to meet the demands of the regenerative medicine industry
AU - Maziarz, Richard T.
AU - Arthurs, Jane
AU - Horwitz, Edwin
PY - 2011/3
Y1 - 2011/3
N2 - The International Society for Cellular Therapy is a global association driving the translation of scientific research to deliver innovative cellular therapies to patients. Established in 1992, its membership and leadership comprises world-class scientists, clinicians, technologists, biotech/pharma and regulatory professionals from 40 countries focused on preclinical and translational aspects of developing cell therapy products. The International Society for Cellular Therapy has evolved in alignment with the maturation of the field of cell therapy and regenerative medicine to create forums for discussion of shared concerns for commercialization of cell therapies and of development of consensus standards, recognizing that true commercialization depends upon the translational scientific community, the regional regulatory and policy institutions, and the technology support and capital investment from industry. It exists to facilitate the international work of many, to spawn new initiatives, and to synergize with other stakeholders to create the best outcome for the many patients across the world depending on the answers and improved health that cellular therapeutics will provide them.
AB - The International Society for Cellular Therapy is a global association driving the translation of scientific research to deliver innovative cellular therapies to patients. Established in 1992, its membership and leadership comprises world-class scientists, clinicians, technologists, biotech/pharma and regulatory professionals from 40 countries focused on preclinical and translational aspects of developing cell therapy products. The International Society for Cellular Therapy has evolved in alignment with the maturation of the field of cell therapy and regenerative medicine to create forums for discussion of shared concerns for commercialization of cell therapies and of development of consensus standards, recognizing that true commercialization depends upon the translational scientific community, the regional regulatory and policy institutions, and the technology support and capital investment from industry. It exists to facilitate the international work of many, to spawn new initiatives, and to synergize with other stakeholders to create the best outcome for the many patients across the world depending on the answers and improved health that cellular therapeutics will provide them.
UR - http://www.scopus.com/inward/record.url?scp=79952601886&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952601886&partnerID=8YFLogxK
U2 - 10.2217/rme.10.102
DO - 10.2217/rme.10.102
M3 - Article
C2 - 21391849
AN - SCOPUS:79952601886
SN - 1746-0751
VL - 6
SP - 163
EP - 166
JO - Regenerative Medicine
JF - Regenerative Medicine
IS - 2
ER -